Hyper-CVAD Treatment in Lymphoblastic Lymphoma

The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01813344

Acronym

LBL-CISL-1

Enrollment

Registered

2013-03-19

Start date

2012-01-31

Completion date

Unknown

Last updated

2013-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoblastic Lymphoma

Keywords

Adult lymphoblastic lymphoma, Hyper-CVAD, first-line treatment

Brief summary

Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.

Detailed description

We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement of response, patients either underwent hematopoietic stem cell transplantation (HSCT) or consolidation with hyper-CVAD.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age over 18 at diagnosis * Pathologically proven lymphoblastic lymphoma

Exclusion criteria

* proven HIV infection * pretreatment with other regimens

Design outcomes

Primary

Measure	Time frame
Overall survival	3-year
Progression free survival	3-year

Secondary

Measure	Time frame
Response Rate	24 weeks

Countries

South Korea

Contacts

Primary ContactSeong Hyun Jeong, MD

seonghyunmd@naver.com+82-31-219-5989

Outcome results